MetLife Inc. Stock: Analyst Outperform Ratings and Undervaluation Signal Potential Upside for Investors

Keefe, Bruyette & Woods reinstated an Outperform rating on MetLife Inc. (NYSE:MET, ISIN: US59156R1086) with an $87 price target as of March 26, 2026. Amid mixed analyst views and signs of undervaluation, North American investors eye the insurer's global operations and segment performance.

MetLife Inc. stands as a cornerstone in the global insurance landscape, with recent analyst actions highlighting its investment appeal. Keefe, Bruyette & Woods reinstated an "Outperform" rating on the company's shares, setting a price target of $87.00, reflecting confidence in its operational strengths.

As of: 27.03.2026

By Elena Vargas, Senior Financial Editor at NorthStar Market Insights: MetLife Inc. navigates a complex insurance sector with diversified global exposure and steady analyst support.

Core Business Model and Global Footprint

MetLife Inc., listed on the NYSE under ticker MET with ISIN US59156R1086, operates as a leading provider of insurance, annuities, and employee benefit programs worldwide. The company traces its roots to 1863, evolving into a multinational enterprise serving millions across diverse markets. Its business model centers on life insurance, group benefits, retirement solutions, and asset management, generating revenue primarily from premiums and investment income.

This diversified approach mitigates risks inherent in single-market dependence. MetLife's U.S. segment forms the backbone, contributing the largest share of earnings through individual and group policies. Internationally, operations span Asia, Latin America, Europe, Middle East, and Africa (EMEA), with Japan as a key hub in Asia.

Investors value MetLife's scale, with a presence in over 40 countries. The company's ability to leverage economies of scale in underwriting and claims processing supports competitive pricing and margins. For North American investors, this global diversification offers exposure to emerging market growth while anchoring in stable domestic demand for retirement and protection products.

Recent Analyst Sentiment and Price Targets

Analyst coverage underscores MetLife's attractiveness, with Keefe, Bruyette & Woods leading recent updates by reinstating Outperform and a $87.00 target on March 26, 2026. This move aligns with a broader consensus where 18 firms rate it 2.1 on a 1-5 scale, signaling Outperform overall.

Other notables include TD Cowen maintaining Buy but adjusting targets downward to $88.00 on March 11, Morgan Stanley holding Overweight at $93.00, and UBS raising to $98.00 earlier. The average one-year target from 13 analysts sits at $91.92, with highs at $103.00 and lows at $80.00.

Such ratings reflect MetLife's resilient earnings profile amid sector headwinds. Investors should monitor consensus shifts, as they often precede price movements. For NYSE:MET traded in USD, these targets suggest potential upside from recent levels around $70.

Segment Performance and Geographic Contributions

MetLife's earnings diversification shines through its segments. The Asia region, driven by Japan, accounts for about 25% of earnings, bolstered by high savings rates and aging demographics. Latin America, with strongholds in Mexico and Chile, contributes roughly 13%, benefiting from expanding middle-class demand for protection products.

U.S. operations dominate, fueled by group benefits and retirement annuities tailored to corporate clients. EMEA adds 4%, while MetLife Holdings, including legacy businesses, provides 10%. This mix balances mature markets' stability with growth markets' potential.

Strategic focus on high-return segments enhances profitability. North American investors gain indirect access to Asia's premium growth without direct exposure risks. Watching quarterly segment reports reveals execution on international expansion.

Valuation Metrics and Undervaluation Signals

Valuation analyses point to MetLife trading below intrinsic worth. One model using excess returns, with book value per share at $43.33 and stable EPS of $8.78, estimates fair value at $193.26, implying 63.6% undervaluation versus recent closes near $70.39.

P/E comparisons show the stock at 14.47x versus a fair ratio of 16.01x, further supporting undervaluation. Book value growth projections to $55.15 per share underpin long-term optimism.

These metrics appeal to value-oriented North American investors seeking insurance sector bargains. However, they assume sustained ROE above cost of equity. Track book value trends and EPS delivery for confirmation.

Relevance for North American Investors

MetLife resonates strongly with North American portfolios due to its dominant U.S. market share in group life and dental insurance. Dividend yields and buybacks provide reliable income, appealing to retirees and institutions. Global diversification hedges U.S.-centric risks like interest rate shifts.

The company's scale enables tech investments in digital underwriting and claims, improving customer retention. For Canadian and U.S. investors, MET offers S&P 500 exposure with international flavor. Pension fund managers favor its liability-matching annuities amid aging populations.

What matters now: alignment of current pricing with analyst targets. Investors should watch dividend sustainability and capital returns, core to total yield calculations.

Risks and Key Open Questions

Insurance faces interest rate sensitivity, with prolonged lows squeezing investment income. MetLife's duration-matched portfolios mitigate this, but rapid hikes could pressure liabilities. Regulatory changes in key markets like Japan pose compliance costs.

Book value declines noted in some analyses highlight cycle pressures, with annual drops of 12.3% over five years in certain views. Growth in net premiums at 2.8% annually trails sector hopes, signaling maturity challenges.

Open questions include Asia execution amid currency volatility and U.S. healthcare reforms. Investors should monitor catastrophe losses and reinsurance costs. Recent mini-tender offers, like the unsupported Potemkin bid at below-market prices, underscore vigilance against opportunistic moves.

North American investors: track Q1 2026 earnings for segment growth and margin updates. Divergent analyst targets signal debate on valuation—watch for resolution.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.